Navigation Links
New combination therapy safe, promising for melanoma patients
Date:6/1/2008

CHICAGO, June 1 The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Researchers in the melanoma and skin cancer program at UPCI combined two biotherapies treatments that stimulate the immune system to fight cancer and found the results promising in terms of anti-tumor effects and tolerable in terms of toxicity. High-dose interferon alfa-2b, a standard treatment for metastatic skin cancer, and tremelimumab, an antibody thought to instigate the bodys immune system to attack tumors, were combined for the first time in this phase 2 clinical trial.

With each new study, we learn something important about melanoma, said John M. Kirkwood, M.D., leader of the program and professor and vice chairman for clinical research in the Department of Medicine, University of Pittsburgh School of Medicine. With this study, we learned that adding tremelimumab to traditional treatment is not only safe, but an effective way to induce an anti-tumor response, which is very exciting.

For this study, 16 patients diagnosed with stage 4 melanoma, all of whom received and had not benefited from at least one round of previous therapy, were given the combination treatment. The overall response rate was 19 percent, and the study has since moved into the second stage, where it will enroll 21 additional patients.

Melanoma is a rare form of skin cancer, but it causes the majority of skin cancer-related deaths. Each year, approximately 160,000 new cases are diagnosed worldwide, and currently surgery is the only effective cure. For patients with inoperable disease, like those enrolled in this study, discovering a safe and effective treatment is vital.


'/>"/>

Contact: Courtney McCrimmon
McCrimmonCP@upmc.edu
412-647-3555
University of Pittsburgh Medical Center
Source:Eurekalert

Page: 1

Related medicine news :

1. Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy
2. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
3. New patient satisfaction study with budesonide/formoterol combination therapy
4. New drug combination brings 1-2 punch against acute leukemia
5. Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study
6. Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack
7. Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
8. Double binding sites on tumor target may provide future combination therapy
9. Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
10. Do bacterial combinations result in enhanced cytokine production? No!
11. Mother-daughter conflict, low serotonin level may be deadly combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology: